Inceptionr LLC acquired a new stake in National Research Co. (NASDAQ:NRC – Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 13,541 shares of the company’s stock, valued at approximately $239,000. Inceptionr LLC owned approximately 0.06% of National Research at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of the business. Charles Schwab Investment Management Inc. grew its stake in National Research by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 124,711 shares of the company’s stock valued at $2,200,000 after buying an additional 970 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of National Research by 10.7% during the 4th quarter. Principal Financial Group Inc. now owns 12,018 shares of the company’s stock valued at $212,000 after purchasing an additional 1,161 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of National Research by 8.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 17,194 shares of the company’s stock valued at $393,000 after purchasing an additional 1,373 shares in the last quarter. SG Americas Securities LLC grew its position in shares of National Research by 35.0% during the 4th quarter. SG Americas Securities LLC now owns 7,298 shares of the company’s stock valued at $129,000 after purchasing an additional 1,893 shares in the last quarter. Finally, Gladius Capital Management LP grew its position in shares of National Research by 164.5% during the 3rd quarter. Gladius Capital Management LP now owns 3,068 shares of the company’s stock valued at $70,000 after purchasing an additional 1,908 shares in the last quarter. 47.26% of the stock is currently owned by hedge funds and other institutional investors.
National Research Stock Up 0.6 %
NRC opened at $15.20 on Tuesday. The company has a fifty day moving average price of $16.72 and a 200-day moving average price of $18.78. The firm has a market capitalization of $356.84 million, a P/E ratio of 14.48 and a beta of 0.47. The company has a debt-to-equity ratio of 1.30, a current ratio of 0.47 and a quick ratio of 0.47. National Research Co. has a one year low of $13.74 and a one year high of $40.69.
About National Research
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.
Further Reading
- Five stocks we like better than National Research
- Breakout Stocks: What They Are and How to Identify Them
- How to Protect Your Portfolio When Inflation Is Rising
- Stock Average Calculator
- 3 Tech Stocks Defying Sector Weakness and Thriving in 2025
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Want to see what other hedge funds are holding NRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for National Research Co. (NASDAQ:NRC – Free Report).
Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.